Cutler Group LP Beam Therapeutics Inc. Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$23.01 - $32.46 $1,150 - $1,623	50 New	50 $1,000
Q3 2022 Oct 25, 2022	SELL	$39.79 - $70.31 $23,714 - $41,904	-596 Reduced 85.63%	100 $4,000
Q2 2022 Aug 04, 2022	SELL	$29.86 - $62.36 $6,837 - $14,280	-229 Reduced 24.76%	696 $26,000
Q1 2022 Apr 14, 2022	BUY	$53.73 - $82.16 $44,327 - $67,782	825 Added 825.0%	925 $53,000
Q4 2021 Jan 18, 2022	SELL	$68.02 - $99.06 $163,248 - $237,744	-2,400 Reduced 96.0%	100 $7,000
Q4 2020 Jan 21, 2021	BUY	$22.24 - $95.63 $55,599 - $239,075	2,500 New	2,500 $204,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.